Micro-Cap Can-Fite BioPharma Shares Surge On Successful Pancreatic Cancer Drug Study

Can-Fite BioPharma Ltd. (AMEX:CANF) shares are up on Wednesday following the company’s announcement that its drug, Namodenoson, successfully met the primary endpoint in a Phase 2a study for pretreated pancreatic cancer patients.Can-Fite BioPharma’s Pancreatic Cancer DataThe Phase 2a study results indicated that Namodenoson demonstrated a significant improvement in overall survival rates among patients, which analysts view as a promising development for Can-Fite.The company reported that the treatment was we ...